SCHEMBL987076

SCHEMBL987076

CC(C)(CC(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.66
GRIN2D O15399 1/20 0.50
GRIN3B O60391 1/20 0.50
GRIN1 Q05586 1/20 0.50
GRIN2A Q12879 1/20 0.50
GRIN2B Q13224 1/20 0.50
GRIN2C Q14957 1/20 0.50
GRIN3A Q8TCU5 1/20 0.50
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
CYP2C19 P33261 3/20 0.47
HIF1A Q16665 1/20 0.47
POLB P06746 1/20 0.46
MAPT P10636 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
PPARA Q07869 1/20 0.43
ME2 P23368 1/20 0.43
ME1 P48163 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3531218 0.85 MIF (0.52) MIFGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3843042 0.84 GRIN2D (0.50) MIFGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL14196061 0.84 GRIN2D (0.50) MIFGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL24020497 0.84 MIF (0.66) MIFGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8476286 0.84 CYP2C19 (0.68) MIFGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL10914051 0.83 CYP2C19 (0.50) MIFCYP2C19HIF1AMAPTCYP3A4
SCHEMBL986565 0.82 GRIN2D (0.53) MIFGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL9076603 0.82 MIF (0.63) MIFGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL5990790 0.82 ESR1 (0.56) MIFCYP2C19HIF1ACYP3A4ME2
SCHEMBL3485439 0.82 CYP2C19 (0.48) MIFKMT2ACYP2C19HIF1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486218-B2 Compounds advantageous in the treatment of central nervous system diseases and disorders AURIMMED PHARMA, INC. (US) 2025-12-02 US disclosed
US-20240425505-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-12-26 US disclosed
US-12110290-B2 Triazolopyridinyl compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-10-08 US disclosed
US-20240239739-A1 COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS AURIMMED PHARMA, INC. 2024-07-18 US disclosed
US-20240239739-A1 COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS AURIMMED PHARMA, INC. 2024-07-18 US disclosed
US-20240239739-A1 COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS AURIMMED PHARMA, INC. 2024-07-18 US disclosed
EP-4364737-A2 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2024-05-08 EP disclosed
EP-4229056-B1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-10 EP disclosed
US-20240109888-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-04 US disclosed
US-11767322-B2 Triazolopyridinyl compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-09-26 US disclosed
US-20020061323-A1 SHAPED BODIES WHICH RELEASE AGROCHEMICAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2002-05-23 US disclosed
EP-0906014-B1 Shaped bodies which release agrochemicals BAYER AG (DE) 2002-03-27 EP disclosed
US-20010039248-A1 Shaped bodies which release agrochemical active substances PODSZUN WOLFGANG (DE) 2001-11-08 US disclosed
EP-0564945-B1 A method of controlling harmful insects BAYER AGROCHEM KK (JP) 2001-01-24 EP disclosed
US-6063393-A RODS OR PINS TO BE PRESSED INTO PLANTS NIHON BAYER AGROCHEM K.K. (JP) 2000-05-16 US disclosed
EP-0906014-A1 SHAPED BODIES WHICH RELEASE AGROCHEMICAL ACTIVE SUBSTANCES BAYER AG (DE) 1999-04-07 EP disclosed
EP-0861024-A1 POLYSACCHARIDE ETHER ESTERS WHICH RELEASE ACTIVE INGREDIENTS BAYER AG (DE) 1998-09-02 EP disclosed
WO-1997046094-A1 SHAPED BODIES WHICH RELEASE AGROCHEMICAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 1997-12-11 WO disclosed
WO-1997017847-A1 POLYSACCHARIDE ETHER ESTERS WHICH RELEASE ACTIVE INGREDIENTS BAYER AKTIENGESELLSCHAFT (DE) 1997-05-22 WO disclosed
EP-0564945-A1 A method of controlling harmful insects NIHON BAYER AGROCHEM K.K. (JP) 1993-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486218-B2 Compounds advantageous in the treatment of central nervous system diseases and disorders SMN1; SMN2, HDAC6, CTSA MIF 1741/4885GRIN2D 94/4885GRIN3B 14/4885
US-20020061323-A1 SHAPED BODIES WHICH RELEASE AGROCHEMICAL ACTIVE SUBSTANCES AGL, CHMP4B, GUSB MIF 3839/4885GRIN2D 4413/4885GRIN3B 4531/4885
US-20010039248-A1 Shaped bodies which release agrochemical active substances AGL, CHMP4B, GUSB MIF 3847/4885GRIN2D 4459/4885GRIN3B 4522/4885
US-20240109888-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 MIF 1154/4885GRIN2D 1733/4885GRIN3B 1126/4885
US-11767322-B2 Triazolopyridinyl compounds as kinase inhibitors RIPK1, RIPK3, RIPK4 MIF 1154/4885GRIN2D 1733/4885GRIN3B 1126/4885
US-12110290-B2 Triazolopyridinyl compounds as kinase inhibitors RIPK1, RIPK3, RIPK4 MIF 1154/4885GRIN2D 1733/4885GRIN3B 1126/4885
US-20240425505-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 MIF 1154/4885GRIN2D 1733/4885GRIN3B 1126/4885
US-20240239739-A1 COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS SMN1; SMN2, HDAC6, CTSA MIF 1741/4885GRIN2D 94/4885GRIN3B 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.